September 24, 2021
The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other […]
September 24, 2021
Transcatheter aortic valve replacement (TAVR) provides comparable stroke and mortality rates out to 1 year in low-risk patients with bicuspid and tricuspid aortic stenosis, registry data suggest. […]
September 23, 2021
Physical activity, long recommended by health experts to reduce risk for obesity, heart disease, type 2 diabetes, high blood pressure, hypercholesterolemia, and other cardiovascular disease risk factors, […]
September 22, 2021
Groundbreaking results from the EMPEROR-Preserved trial did more than establish for the first time that a drug, empagliflozin, has clearly proven efficacy for treating patients with […]
September 22, 2021
Patients with ST-segment elevation myocardial infarction (STEMI) who delay seeking care for more than 12 hours still derive significant benefit from coronary revascularization of the infarct […]
September 22, 2021
NEW YORK (Reuters Health) – Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say. […]
September 21, 2021
A large multicenter study provides further evidence supporting the rationale for multidisciplinary teams for cardiogenic shock, one of the most lethal diseases in cardiovascular medicine. The […]
September 20, 2021
The US Food and Drug Administration has approved the Portico with FlexNav (Abbott) transcatheter aortic valve replacement (TAVR) system for patients with “symptomatic, severe aortic stenosis […]
September 17, 2021
The American Heart Association (AHA) has reversed its earlier decision to offer a hybrid format for the 2021 Scientific Sessions in Boston in November, going instead […]